Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Chihcheng Hsu who wrote (6304)	11/17/1998 6:35:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

CH, Celebrex is a COX-2 inhibitor developed by GD Searle, a division of Monsanto (MTC). Pfizer paid Monsanto $140 million for the marketing deal, and has already spent $100 million in the last quarter hiring sales representatives in preparation for marketing Celebrex. This is considered to be a blockbuster drug by most drug analysts, but how much Pfizer will get from marketing this drug is unknown. There were a lot of recent news on Celebrex because of the American College of Rheumatology annual meeting held last week. Do a "Celebrex" search on this thread or the MTC thread to read them. The following is one of them: Message 6369733 Dec. 1 & 2 are the dates when the FDA advisory committee review Celebrex. A positve recommenation to the FDA usually means that the drug would be approved. A relevant article on the review: techstocks.com Anthony